| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Rivaroxaban : 90981
Test CodeRIVBAN or 90981
Alias/See Also
Xarelto
CPT Codes
80299
Preferred Specimen
1 mL frozen plasma collected in a 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
Instructions
Collect samples 2-4 hours post dose (peak)
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 28 days
Refrigerated: Unacceptable
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Thawed plasma, Hemolysis
Methodology
Chromogenic
Setup Schedule
Mon, Wed, Fri
Report Available
1-4 days (From receipt at performing laboratory)
Limitations
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Reference Range
Dosage Peak (steady state) mcg/L Trough* mcg/L
20 mg qD 182 - 408 3 - 153
15 mg qD 180 - 408 2 - 161
10 mg qD 91 - 196 1 - 38
* The lower limit of detection for this assay is 30 mcg/L.
20 mg qD 182 - 408 3 - 153
15 mg qD 180 - 408 2 - 161
10 mg qD 91 - 196 1 - 38
* The lower limit of detection for this assay is 30 mcg/L.
Clinical Significance
Rivaroxaban is an oral factor Xa inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also indicated for the treatment, prophylaxis, or the reduction in the risk of reoccurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). Rivaroxaban does not need to be monitored routinely, however, exceptions may include determination of failure of therapy vs. poor compliance, or potential dose adjustment required for renal or hepatic dysfunction.
Performing Laboratory
Quest Diagnostics
